If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
214
results.
Updated on
16/02/2026 [06:51:00]
Results 200 to 214 of 214
Absstract of: MX2024001081A
The present disclosure provides nanoemulsions comprising one or more active ingredients (e.g., one or more cannabinoid and/or cannabimimetics), formulated for use as tinctures or shots. Such nanoemulsions, tinctures, and shots can exhibit high physical stability, e.g., exhibiting no observable phase separation over a period of 6 months or more or 12 months or more.
Absstract of: AU2024307171A1
A pharmaceutical composition containing a cationic lipid and the use thereof. Specifically, provided are a pharmaceutical composition comprising a carrier, the carrier comprising a cationic lipid, and the molar percentage of the cationic lipid to the carrier being greater than or equal to 10% and less than 50%.
Absstract of: TW202517243A
The present invention provides, in part, dianhydrohexitol-based cationic lipids of Formula (I), and sub-formulas thereof:, or a pharmaceutically acceptable salt thereof. The present invention also provides, in part, dianhydrohexitol-based cationic lipids of Formula (II), and sub-formulas thereof:, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Absstract of: AU2025263792A1
COMPOSITIONS AND METHODS FOR TREATING NON-AGE- ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject. COMPOSITIONS AND METHODS FOR TREATING NON-AGE- ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject. ov - - o v
Absstract of: AU2023455215A1
Provided herein are novel constructs comprising gold nanoparticles bound to two types of cytokines, wherein the two types of cytokines comprise Tumor Necrosis Factor alpha (TNF ) and a cytokine selected from the group consisting of Interferon gamma (IFN ) and lnterleukin-12. Further provided is a method for treating cancer in a subject in need thereof.
Absstract of: WO2025003760A1
Provided are lipid nanoparticles for delivering nucleic acids molecules such as mRNA. Also provided are methods of making and using thereof.
Absstract of: TW202517243A
The present invention provides, in part, dianhydrohexitol-based cationic lipids of Formula (I), and sub-formulas thereof:, or a pharmaceutically acceptable salt thereof. The present invention also provides, in part, dianhydrohexitol-based cationic lipids of Formula (II), and sub-formulas thereof:, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Absstract of: TW202515513A
Provided are lipid nanoparticles for delivering nucleic acids molecules such as mRNA. Also provided are methods of making and using thereof.
Absstract of: AU2024281932A1
Provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same for treating drug addiction, drug dependence, drug overdose, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity.
Absstract of: AU2024309710A1
Described is a method for the preparation of an aqueous mesoparticle composition comprising a lipophilic compound, comprising the steps of: a. Providing an emulsifier or a blend of emulsifiers in powder form; b. Mixing one or more oils at a temperature above 40°C where all oils have become liquid, wherein said oils differ in melting temperature and which mixture comprises at least a sufficient amount of medium chain triglycerides to enable the composition formed in step g have a partly liquid oil phase at temperatures around about 4°C; c. Adding the hydrophobic or amphiphilic compound in any hydrophobic solvent to the oil mixture; d. Optionally letting the mixture cool down to room temperature; e. Adding the emulsifier powder and water to the oil mixture and letting the mixture emulsify, under optional agitation and heating to 30-40°C; f. Subjecting the emulsified mixture to a sonication and optionally mixing or fluidisation treatment until the average particle size of the mixture remains stable; g. Cooling down the sonicated mixture allowing sufficient time for crystallisation; and h. Optionally, a second sonication treatment while keeping the mixture cold and compositions produced by the above method.
Absstract of: AU2024314758A1
The present invention relates to compositions comprising sHDL nanoparticles. In particular, the present invention relates to sHDL nanoparticles comprising a phospholipid; an apoplipoprotein mimetic; a thiol-reactive lipid; and a peptide comprising a linker moiety connected with a payload moiety, wherein the linker comprises cysteine (C) and one to five amino acids independently selected from aspartic acid (D), glutamic acid (E), and serine (S), the payload comprises a polypeptide that is 5 to 35 amino acids in length and has a net positive charge at a pH of 7 to 12, and the peptide comprises a net negative charge at a pH of 7 and an isoelectric point of 0.4 to 12; and wherein the peptide is covalently attached to the thiol-reactive lipid by way of the cysteine (C).
Absstract of: US2024423914A1
Compounds are provided having the following Formula (I):or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein G1, R1, R2, R3, L1, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Absstract of: US2025025427A1
Compounds are provided having the following Formula (I):or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein G1, G2, R1, R2, R3, L1a, L1b, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Nº publicación: IL325487A 01/02/2026
Applicant:
ETHERNA IMMUNOTHERAPIES NV [BE]
KASMI SABAH [BE]
DE COEN RUBEN [BE]
DE KOKER STEFAAN [BE]
DUMBRE SHRINIVAS [BE]
ETHERNA IMMUNOTHERAPIES NV,
KASMI Sabah,
DE COEN Ruben,
DE KOKER Stefaan,
DUMBRE Shrinivas
Absstract of: TW202517616A
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by formula (I). The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising active agents. It further provides pharmaceutical formulations comprising nanoparticle compositions based on the ionizable lipids disclosed herein.
BOPI
Electronic site
